Acarbose 100mg tablets
Requires a prescription from a doctor or prescriber
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Acarbose
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Acarbose
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Acarbose
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
20 branded products available
MHRA licensed products
View all licensed products for Acarbose on the MHRA register
Acarbose 100mg tablets
Acarbose 100mg tablets
Acarbose 100mg tablets
Acarbose 100mg tablets
Acarbose 100mg tablets
Acarbose 100mg tablets
Acarbose 100mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
300 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Type 2 diabetes: insulin degludec (ESNM25)
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 11 · 1991–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Hanefeld, M. Çağatay, T. Petrowitsch, et al.
European heart journal, 2004
- Diabetes Mellitus, Type 2
- Diabetic Angiopathies
- Enzyme Inhibitors
Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan, et al.
The Lancet Diabetes & Endocrinology, 2017
- Cardiovascular Diseases
- Coronary Disease
- Diabetes Mellitus, Type 2
Xiuying Zhang, Zhiwei Fang, Chunfang Zhang, et al.
Diabetes Therapy, 2017
Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis, et al.
The Lancet, 2002
- Blood Glucose
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
Rury R. Holman, C A Cull, R. C. Turner
Diabetes Care, 1999
- Albuminuria
- Blood Glucose
- Body Weight
Wenying Yang, Jie Liu, Zhongyan Shan, et al.
The Lancet Diabetes & Endocrinology, 2013
- Blood Glucose
- China
- Diabetes Mellitus, Type 2
Changyu Pan, Wenying Yang, Jacqueline Barona, et al.
Diabetic Medicine, 2008
- Vildagliptin
- Adamantane
- Blood Glucose
Matteo Monami, Valentina Vitale, Maria Luisa Ambrosio, et al.
Advances in Therapy, 2012
- Pioglitazone
- Diabetes Mellitus, Type 2
- Hypercholesterolemia
Qibo Zhu, Yuzhen Tong, Taixiang Wu, et al.
Clinical Therapeutics, 2013
- Diet
- Diabetes Mellitus, Type 2
- Dietary Carbohydrates
Giuseppe Derosa, Pamela Maffioli
Clinical Therapeutics, 2012
- Hypoglycemic Agents
- Placebos
- Acarbose
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2 hours
Mechanism
Alpha-glucosidase enzymes are located in the brush-border of the intestinal muco…
Food interactions
1 warning
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1-2%
Half-life
2 hours
[L31628]
Protein binding
1-2%
[L31633]
…
Metabolism
Elimination
96 hours
[L31633]
…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued).[L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal adverse effects.[L31668]
[L31628]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 611 interactions
[L31628]
In the event of an overdose, patients should be instructed to avoid carbohydrate-containing foods for 4-6 hours following administration as these can precipitate the aforementioned GI symptoms.
[L31628]
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - of the alpha-glucosidases, inhibitory potency appears to follow a rank order of glucoamylase > sucrase > maltase > isomaltase.[L31633] By preventing the metabolism and subsequent absorption of dietary carbohydrates, acarbose reduces postprandial blood glucose and insulin levels.
Given its mechanism of action, acarbose in isolation poses little risk of contributing to hypoglycemia - this risk is more pronounced, however, when acarbose is used in conjunction with other antidiabetic therapies (e.g. sulfonylureas, insulin).[L31633] Patients maintained on acarbose in addition to other antidiabetic agents should be aware of the symptoms and risks of hypoglycemia and how to treat hypoglycemic episodes. There have been rare post-marketing reports of the development of pneumatosis cystoides intestinalis following treatment with alpha-glucosidase inhibitors - patients experiencing significant diarrhea/constipation, mucus discharge, and/or rectal bleeding should be investigated and, if pneumatosis cystoides intestinalis is suspected, should discontinue therapy.[L31628]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L31628]
[L31628]
[L31633]
[L31628]
Only one metabolite - resulting from the cleavage of a glucose molecule from acarbose - has been identified as having alpha-glucosidase inhibitory activity.
[L31628]
[L31633]
What little drug material is absorbed into the systemic circulation (approximately 34% of an orally administered dose) is excreted primarily by the kidneys, suggesting renal excretion would be a significant route of elimination if the parent drug was more readily absorbed - this is further supported by data in which approximately 89% of an intravenously administered dose of acarbose was excreted in the urine as active drug (in comparison to <2% following oral administration) within 48 hours.
[L31633]
Proteins and enzymes this drug interacts with in the body
PMID:12547908 PMID:18036614 PMID:18356321 PMID:22058037 PMID:27480812
Mainly hydrolyzes short length oligomaltoses having two to seven glucose residues .
PMID:12547908 PMID:18036614 PMID:18356321 PMID:22058037 PMID:27480812
Can cleave alpha-(1,2), alpha-(1,3) and alpha-(1,6) glycosidic linkages with lower efficiency, whereas beta glycosidic linkages are usually not hydrolyzed PMID:27480812
PMID:14695532 PMID:18429042 PMID:1856189 PMID:7717400
Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans PMID:29061980
ATC A10BD17
ATC A10BF01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Acarbose
Additional database identifiers
Drugs Product Database (DPD)
917
ChemSpider
23264314
ZINC
ZINC000096309558
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7043
GenAtlas
MGAM
GeneCards
MGAM
GenBank Gene Database
AF016833
GenBank Protein Database
17648144
Guide to Pharmacology
2627
UniProt Accession
MGA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10856
GenAtlas
SI
GeneCards
SI
GenBank Gene Database
X63597
GenBank Protein Database
36645
UniProt Accession
SUIS_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:477
GenAtlas
AMY2A
GeneCards
AMY2A
GenBank Gene Database
M18785
UniProt Accession
AMYP_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4065
GenAtlas
GAA
GeneCards
GAA
GenBank Gene Database
Y00839
GenBank Protein Database
31608
Guide to Pharmacology
2611
UniProt Accession
LYAG_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72